H7N9 Influenza Vaccine Clinical Trials Begin
H7N9 is an avian influenza virus with pandemic potential. To date, only a few infections in humans have been found, all outside of the United States. However, should the virus change to transmit more easily between people, it could cause widespread suffering: H7N9 has a high mortality rate for a flu virus.
To prepare for this possibility, NIAID is sponsoring two new Phase 2 trials of an H7N9 inactivated influenza vaccine, which may provide protection against the virus. The trials, conducted through the Vaccine and Treatment Evaluation Unit (VTEU) network, will test the vaccines at various doses, with and without adjuvant, and in conjunction with the seasonal influenza vaccine.